<?xml version='1.0' encoding='utf-8'?>
<document id="31090382"><sentence text="Significance of L-carnitine in internal medicine."><entity charOffset="16-27" id="DDI-PubMed.31090382.s1.e0" text="L-carnitine" /></sentence><sentence text="The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases"><entity charOffset="112-123" id="DDI-PubMed.31090382.s2.e0" text="L-carnitine" /></sentence><sentence text=" Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists"><entity charOffset="75-86" id="DDI-PubMed.31090382.s3.e0" text="L-carnitine" /></sentence><sentence text=" Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4"><entity charOffset="63-74" id="DDI-PubMed.31090382.s4.e0" text="L-carnitine" /></sentence><sentence text=" When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine"><entity charOffset="12-23" id="DDI-PubMed.31090382.s5.e0" text="L-carnitine" /><entity charOffset="129-140" id="DDI-PubMed.31090382.s5.e1" text="L-carnitine" /><pair ddi="false" e1="DDI-PubMed.31090382.s5.e0" e2="DDI-PubMed.31090382.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31090382.s5.e0" e2="DDI-PubMed.31090382.s5.e1" /></sentence><sentence text=" Keywords: L-carnitine, P450 CYP 3А4, chronic heart failure, myocardial infarction, chronic renal failure, inter-drug interaction, antioxidant, antihypoxant"><entity charOffset="11-22" id="DDI-PubMed.31090382.s6.e0" text="L-carnitine" /></sentence><sentence text="" /></document>